Navigation Links
Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pfizer Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0188870/Pfizer-Inc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

  • Benchmark Pfizer's performance against key rivals in the prescription pharmaceutical sector
  • Assess how Pfizer's M&A driven growth strategy will impact the company's commercial performance through to 2015
  • Analyze the impact of patent expiry for Pfizer's flagship product Lipitor

  • ABOUT DATAMONITOR HEALTHCARE 2

    About the PharmaVitae team 2

    Chapter 1 About this profile 3

    PharmaVitae Explorer database 3

    Chapter structure 3

    Executive summary 3

    Quarterly update 3

    Company introduction 3

    Company sales 4

    Company financials 4

    Key products 4

    Data sourcing 4

    Sales data 4

    Analyst consensus 4

    Chapter 2 Executive summary 5

    Key findings 5

    Prescription pharmaceutical sales and growth rate performance, 2003-15 6

    Financial performance, 2003-15 7

    Pfizer: PharmaVitae forecasts at a glance 8

    Strategic insight 9

    Wyeth acquisition the latest in a succession of large scale M&A 'plays' by Pfizer 9

    Diversification strategy at heart of Wyeth M&A 11

    Outlook - will Pfizer return to the M&A trail before 2015? 16

    SWOT analysis 19

    Table of Contents 20

    Table of figures 22

    Chapter 3 Quarterly news update 23

    Latest quarterly sales 23

    Latest comment 24

    Hope for an Alzheimer's breakthrough remains despite Dimebon's failure 24

    Pfizer's novel NGF pain drug is potential game changer 25

    Pfizer: Lyrica sNDA withdrawal no cause for anxiety 26

    Latest prescription pharma product news 27

    Q4 2009 29

    Q3 2009 32

    Q1 2009 33

    Latest corporate news 35

    Q1 2010 35

    Q4 2009 35

    Q3 2009 36

    Q2 2009 36

    Q1 2009 37

    Future product milestones 39

    Chapter 4 Company introduction 41

    Key findings 41

    Background 42

    Key corporate developments 42

    M&A history 42

    Warner-Lambert acquisition 43

    Pharmacia acquisition 43

    Chapter 5 Company sales 46

    Key findings 46

    Prescription pharmaceutical sales and growth rate analysis, 2003-15 47

    Product analysis 49

    Product analysis, 2003-09 50

    Product analysis, 2009-15 53

    Therapy area analysis 56

    Geographic analysis 59

    Launch/core/expiry analysis 60

    Explanation of launch/core/expiry analysis 60

    Launch analysis, 2009-15 61

    Core analysis, 2009-15 63

    Expiry analysis, 2009-15 64

    Launch/core/expiry configuration, 2009-15 66

    Molecule type analysis 69

    Externalization analysis 71

    Chapter 6 Company financials 73

    Key findings 73

    Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 74

    Operating costs and profit analysis 75

    Operating costs and profit analysis, 2002-08 76

    Operating cost ratio and profit margin analysis, 2003-09 77

    Operating cost ratio and profit margin analysis, 2009-15 78

    Operating costs and profit analysis, 2009-15 79

    Chapter 7 Key products 81

    Overview 81

    Prevnar 82

    Summary 82

    Sales forecast 83

    Enbrel 84

    Summary 84

    Sales forecast 85

    Bapineuzumab 86

    Summary 86

    Sales forecast 87

    Sutent 88

    Summary 88

    Sales forecast 89

    Tygacil 90

    Summary 90

    Sales forecast 91

    Lipitor 92

    Summary 92

    Sales forecast 93

    Celebrex 94

    Summary 94

    Sales forecast 95

    Viagra 96

    Summary 96

    Sales forecast 97

    Xalatan/Xalacom 98

    Summary 98

    Sales forecast 99

    Detrol/Detrol LA 100

    Summary 100

    Sales forecast 101

    Chapter 8 Appendix 103

    Abbreviations 103

    Exchange rates 104

    About Datamonitor 105

    About Datamonitor Healthcare 105

    Datamonitor consulting 105

    Disclaimer 107

    List of Tables Table 1: Pfizer - PharmaVitae forecasts at a glance 8

    Table 2: Pfizer quarterly sales ($m), Q408-Q409 23

    Table 3: Pfizer future product milestones, 2009-11 39

    Table 4: Pfizer product portfolio overview ($m), 2003-09 50

    Table 5: Pfizer product portfolio overview ($m), 2009-15 53

    Table 6: Pfizer prescription pharmaceutical sales by therapy area ($m), 2009-15 58

    Table 7: Pfizer prescription pharmaceutical sales by geographic region ($m), 2009-15 60

    Table 8: Pfizer launch portfolio overview ($m), 2009-15 61

    Table 9: Pfizer core portfolio overview ($m), 2009-15 63

    Table 10: Pfizer expiry portfolio overview ($m), 2009-15 64

    Table 11: Pfizer prescription pharmaceutical sales by molecule type ($m), 2009-15 70

    Table 12: Pfizer prescription pharmaceutical sales by source ($m), 2009-15 72

    Table 13: Total Pfizer sales by business unit ($m), 2003-09 74

    Table 14: Pfizer operating revenue/cost analysis ($m), 2003-09 76

    Table 15: Pfizer operating cost ratio analysis (% of total revenues), 2003-09 77

    Table 16: Pfizer operating cost ratio analysis (% of total revenues), 2009-15 78

    Table 17: Pfizer operating revenue/cost analysis ($m), 2008-14 79

    Table 18: Pfizer Key products overview 81

    Table 19: Prevnar: overview 82

    Table 20: Prevnar: sales forecast ($m), 2009-15 83

    Table 21: Enbrel: overview 84

    Table 22: Enbrel: sales forecast ($m), 2009-15 85

    Table 23: Bapineuzumab: overview 86

    Table 24: Bapineuzumab: sales forecast ($m), 2009-15 87

    Table 25: Sutent: overview 88

    Table 26: Sutent: sales forecast ($m), 2009-15 89

    Table 27: Tygacil: overview 90

    Table 28: Tygacil: sales forecast ($m), 2009-15 91

    Table 29: Lipitor: overview 92

    Table 30: Lipitor: sales forecast ($m), 2009-15 93

    Table 31: Celebrex: overview 94

    Table 32: Celebrex: sales forecast ($m), 2009-15 95

    Table 33: Viagra: overview 96

    Table 34: Viagra: sales forecast ($m), 2009-15 97

    Table 35: Xalatan/Xalacom: overview 98

    Table 36: Xalatan/Xalacom: sales forecast ($m), 2009-15 99

    Table 37: Detrol/Detrol LA: overview 100

    Table 38: Detrol/Detrol LA: sales forecast ($m), 2009-15 101

    Table 39: Exchange rates, 2010 104

    List of Figures Figure 1: The PharmaVitae Explorer 3

    Figure 2: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

    Figure 3: Pfizer's financial performance ($m), 2003-15 7

    Figure 4: Pfizer prescription pharmaceutical sales by M&A component ($m), 2000-15 9

    Figure 5: Pfizer launch/core/expiry configuration ($m), 2009-15 + impact of Wyeth M&A 10

    Figure 6: Pfizer launch/core/expiry configuration ($m), 2009-15 + impact of Wyeth M&A (adjusted for M&A scale impact) 11

    Figure 7: Pfizer prescription pharmaceutical sales by molecule type ($m), 2003-15 12

    Figure 8: Pfizer prescription pharmaceutical sales by therapy area (%), 2003-15 13

    Figure 9: Summary of structural changes at Pfizer since 2008 14

    Figure 10: Pfizer total sales ($m), 2003-15 15

    Figure 11: Pfizer total sales, operating profit, M&A synergies and cost savings ($m), 2003-15 16

    Figure 12: Potential M&A targets for Pfizer in 2014 ($m) 18

    Figure 13: Pfizer SWOT analysis 19

    Figure 14: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 47

    Figure 15: Pfizer Key product sales ($m), 2003-15 49

    Figure 16: Pfizer key sales growth drivers and resistors ($m), 2003-09 52

    Figure 17: Pfizer key sales growth drivers and resistors ($m), 2009-15 55

    Figure 18: Pfizer prescription pharmaceutical sales by therapy area ($m), 2003-15 56

    Figure 19: Pfizer prescription pharmaceutical sales by geographic region ($m), 2003-15 59

    Figure 20: Pfizer launch/core/expiry configuration ($m), 2009-15 66

    Figure 21: Pfizer launch/core/expiry configuration ($m), 2009-15 + impact of Wyeth M&A 67

    Figure 22: Pfizer launch/core/expiry configuration ($m), 2009-15 + impact of Wyeth M&A (adjusted for M&A scale impact) 68

    Figure 23: Pfizer prescription pharmaceutical sales by molecule type ($m), 2003-15 69

    Figure 24: Pfizer prescription pharmaceutical sales by source ($m), 2003-15 71

    Figure 25: Pfizer operating revenue/cost analysis ($m), 2003-15 75

    To order this report:Pharmaceutical Industry: Pfizer Inc.: PharmaVitae Profile

    Pharmaceutical Business News

    More Market Research Report

    Check our Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds US Disposable Medical Supplies Market Report
    2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
    3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
    4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
    5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
    6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
    7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
    8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
    9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
    10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
    11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
    (Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
    (Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ... the "Label-Free Detection Market by Technology, ... report to their offering. --> ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... ... 2016 , ... Local insurance agency Dennis Fuller & Associates, ... initiated a fundraiser for a two year old little girl named Bella, whose ... support this beautiful child who is facing life’s journey without her loving mother, ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
    (Date:2/8/2016)... Gaithersburg, MD (PRWEB) , ... February 08, 2016 ... ... (AHCC) is excited to share this important news! AHCC and the Home Health ... (AHA) Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to ...
    (Date:2/8/2016)... ... 08, 2016 , ... The schedule is now online for the ... Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues ... and causes of chronic illness in children. , Very recent articles have cited 1 ...
    (Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
    Breaking Medicine News(10 mins):